[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 576 Engrossed in House (EH)]


                 In the House of Representatives, U.S.,

                                                    September 27, 2000.
Whereas an estimated 12,400 children will be diagnosed with cancer in the year 
        2000;
Whereas cancer is the leading cause of death by disease in children under age 
        15;
Whereas an estimated 2,300 children will die from cancer in the year 2000;
Whereas the incidence of cancer among children in the United States is rising by 
        about one percent each year;
Whereas 1 in every 330 Americans develops cancer before age 20;
Whereas approximately 8 percent of deaths of those between 1 and 19 years old 
        are caused by cancer;
Whereas a number of opportunities for childhood cancer research remain unfunded 
        or underfunded;
Whereas limited resources for childhood cancer research hinder the recruitment 
        of investigators and physicians to pediatric oncology;
Whereas peer-reviewed clinical trials are the standard of care for pediatrics 
        and have improved cancer survival rates among children; and
Whereas a recent study indicates that, based on parental reports, 89 percent of 
        children with cancer experienced substantial suffering in the last month 
        of life: Now, therefore, be it
    Resolved, That it is the sense of the House of Representatives that Congress 
should support--
            (1) public and private sector efforts to promote awareness about the 
        incidence of cancer among children, the signs and symptoms of cancer in 
        children, and treatment options;
            (2) increased public and private investment in childhood cancer 
        research to improve prevention, diagnosis, treatment, and long-term 
        survival;
            (3) policies that provide incentives to encourage medical trainees 
        and investigators to enter the field of pediatric oncology;
            (4) policies that provide incentives to encourage the development of 
        drugs and biologics designed to treat pediatric cancers;
            (5) policies that encourage participation in clinical trials; and
            (6) medical education curricula designed to improve pain management 
        for cancer patients.
            Attest:

                                                                          Clerk.